Viracta Therapeutics, Inc. (VIRX)
NASDAQ: VIRX · Real-Time Price · USD
0.196
-0.004 (-2.00%)
At close: Nov 5, 2024, 4:00 PM
0.204
+0.008 (3.98%)
After-hours: Nov 5, 2024, 5:37 PM EST
Viracta Therapeutics Employees
Viracta Therapeutics had 40 employees as of December 31, 2023. The number of employees increased by 8 or 25.00% compared to the previous year.
Employees
40
Change (1Y)
8
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,133,400
Market Cap
7.73M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 40 | 8 | 25.00% |
Dec 31, 2022 | 32 | 8 | 33.33% |
Dec 31, 2021 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
CareMax | 1,450 |
NeuroMetrix | 26 |
Pulmatrix | 22 |
Plus Therapeutics | 20 |
ABVC BioPharma | 19 |
Soligenix | 15 |
NLS Pharmaceutics AG | 7 |
Ensysce Biosciences | 7 |
VIRX News
- 2 months ago - Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer - GlobeNewsWire
- 6 months ago - Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 7 months ago - Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma - GlobeNewsWire
- 7 months ago - Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan - GlobeNewsWire